Where do Monte Rosa Therapeutics, Inc.'s ratios come from?

Every ratio is computed from Monte Rosa Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Profitability
Operating margin	-345.2%—	-43.8%—	——	——	——
Net margin	-302.6%—	-31.2%—	——	——	——
EBITDA margin	-325.8%—	-37.1%—	——	——	——
Free cash flow margin	-45.8%-64.9pp	-22.2%-72.5pp	79.9%—	13.4%—	19.1%—
Returns
Return on equity	-32.6%—	-16.9%—	——	——	——
Return on assets	-23%—	-8.7%—	——	——	——
Return on invested capital	-46.4%—	-59%—	——	——	——
Efficiency
Asset turnover	0.1×-0.4×	0.3×+0.1×	0.5×+0.4×	0.5×+0.5×	0.5×+0.5×
Liquidity
Current ratio	9.5×+3.9×	6.1×+3.7×	6.5×+0.5×	7.2×+0.6×	5.6×+0.8×
Quick ratio	9.5×+3.9×	6.1×+3.7×	6.5×+0.5×	7.2×+0.6×	5.6×+0.8×
Cash ratio	2.3×+0.9×	2×+0.6×	3.4×+0.4×	1.7×-0.9×	1.3×-1.1×
Leverage
Debt-to-equity	0.1×-0.1×	0.2×0.0×	0.2×0.0×	0.2×0.0×	0.2×-0.1×
Debt-to-assets	0.1×-0.1×	0.1×0.0×	0.1×-0.1×	0.1×0.0×	0.1×-0.1×
Interest coverage	-9.8×—	-4.2×—	——	——	——
Per Share
Book value per share	$5.23+57.5%	$2.81-7.0%	$2.98+19.1%	$3.26+3.4%	$3.32+30.8%
Valuation
Market capitalization	$1.32B+361%	$1.02B+139%	$457.64M+5.3%	$291.56M+9.4%	$285.41M-32.7%
Enterprise value	$1.2B+381%	$930.35M+280%	$289.46M-17.9%	$263.26M+30.4%	$248.74M-32.7%
Price / sales	30.6×+28.9×	8.3×+2.6×	2.5×-26.5×	1.6×-44.6×	1.8×-397×
Price / book	2.5×+1.5×	4.4×+2.5×	1.9×-0.3×	1.1×-0.1×	1×-1.7×
EV / sales	27.8×+26.3×	7.5×+4.3×	1.6×-22.0×	1.5×-33.6×	1.6×-346×
Free cash flow yield	-1.5%-12.2pp	-2.7%-11.6pp	31.7%—	8.2%—	10.7%—
Earnings yield	-9.9%—	-3.8%—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where do Monte Rosa Therapeutics, Inc.'s ratios come from?: Every ratio is computed from Monte Rosa Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.